Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items (2016 - 2023)

Editas Medicine (EDIT) has disclosed Non-cash Items for 9 consecutive years, with $2.6 million as the latest value for Q2 2023.

  • On a quarterly basis, Non-cash Items rose 39.31% to $2.6 million in Q2 2023 year-over-year; TTM through Jun 2023 was $2.6 million, a 39.31% increase, with the full-year FY2022 number at $401.5 million, up 27591.85% from a year prior.
  • Non-cash Items was $2.6 million for Q2 2023 at Editas Medicine, up from $2.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.1 billion in Q4 2021 to a low of $1.3 million in Q3 2021.
  • A 5-year average of $540.9 million and a median of $3.5 million in 2020 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: surged 262951.33% in 2022, then plummeted 99.95% in 2023.
  • Editas Medicine's Non-cash Items stood at $26.1 million in 2019, then soared by 543.28% to $167.6 million in 2020, then skyrocketed by 2913.88% to $5.1 billion in 2021, then plummeted by 92.05% to $401.5 million in 2022, then plummeted by 99.36% to $2.6 million in 2023.
  • Per Business Quant, the three most recent readings for EDIT's Non-cash Items are $2.6 million (Q2 2023), $2.2 million (Q1 2023), and $401.5 million (Q4 2022).